New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.92 2.18 +1.64%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Ratios over time FY16 to FY25

Returns on capital

ROIC was 16.3% in FY25, against a low of 2.87% in FY23. ROE, at 36.9%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE9.2%6.4%20.2%37.2%27.5%41.0%34.4%0.9%40.8%36.9%
ROIC6.8%9.0%14.8%12.9%8.1%13.6%18.6%2.9%18.8%16.3%

Debt

Net debt is 1.15× a year’s EBITDA. Debt is 0.89× equity, against 1.00× in FY20.

Debt / equityNet debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Debt / equity0.6×0.6×0.7×0.9×1.0×0.8×0.6×0.9×0.7×0.9×
Net debt / EBITDA0.9×1.1×0.8×1.1×1.9×1.4×0.7×3.9×0.8×1.2×

Cash cycle, in days

Customers pay in 66 days, inventory is held 148 days and suppliers are paid in 98. Cash is tied up for 116 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle1181191181319310593118107116
Days to pay suppliers73889011411612389899898
Days to be paid64636163606958635866

Per share, from FY16

Since FY16, per share: free cash flow has grown 5.06% a year; revenue has grown 6.79% a year; book value has grown 4.17% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×0.5×1.0×0.7×0.4×1.1×1.8×1.1×2.3×1.6×
Revenue1.0×1.0×1.1×1.1×1.1×1.3×1.6×1.6×1.8×1.8×
Book value1.0×0.9×0.7×0.7×0.7×1.0×1.2×1.0×1.3×1.4×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
41.49 58.34 31.78 23.04 28.50 14.85 19.40 808.86 14.78 14.46
Piotroski F-Score
7 7 8 6 5 8 7 5 9 4
Altman Z-Score
3.14 3.12 3.76 3.93 3.19 3.38 4.68 3.84 4.11 3.77
P/S ratio
4.03 3.69 4.64 5.75 4.81 3.98 4.75 4.78 3.93 4.05
P/FCF ratio
18.33 32.46 23.65 40.82 62.65 22.35 19.13 31.42 13.92 21.31
Altman Z″-Score (non-manufacturers)
3.59 3.19 3.20 3.31 2.53 3.49 4.41 2.80 4.18 4.21
Beneish M-Score
(2.76) (2.72) (2.78) (2.70) (2.61) (2.17) (2.62) (3.01) (2.69) (2.27)
P/Operating CF
44.21 36.86 54.69 945.92 58.57 38.06 63.52 1,167.85 73.01 92.18
P/B ratio
3.98 4.29 7.31 8.66 7.86 5.07 6.11 7.63 5.43 5.00
EV/Sales
4.28 4.01 4.90 6.07 5.23 4.45 5.01 5.22 4.25 4.55
EV/EBITDA
15.54 14.03 15.42 21.13 24.02 13.19 13.38 45.98 11.03 10.58
EV/FCF
19.46 35.28 24.97 43.05 68.08 24.96 20.19 34.33 15.07 23.91
Current Ratio
1.78 1.33 1.17 1.24 1.02 1.27 1.47 1.25 1.36 1.54
Net Debt/EBITDA
0.91 1.12 0.81 1.09 1.92 1.38 0.70 3.90 0.84 1.15
Debt/Equity
0.60 0.62 0.74 0.87 1.00 0.80 0.62 0.90 0.74 0.89
ROE
9.22% 6.39% 20.24% 37.23% 27.50% 41.00% 34.44% 0.87% 40.75% 36.86%
ROA
3.98% 2.61% 7.30% 11.79% 8.03% 13.23% 13.52% 0.34% 15.30% 14.37%
ROIC
6.84% 8.96% 14.76% 12.94% 8.12% 13.56% 18.55% 2.87% 18.82% 16.28%
Return on Tangible Assets
15.41% 12.88% 36.67% 48.45% 40.53% 50.83% 44.12% 1.24% 50.14% 45.07%
Average Days of Receivables
64.35 62.53 61.02 63.24 59.81 69.17 58.18 62.84 58.46 66.11
Earnings Yield
2.41% 1.71% 3.15% 4.34% 3.51% 6.73% 5.16% 0.12% 6.77% 6.92%
Free Cash Flow Yield
5.46% 3.08% 4.23% 2.45% 1.60% 4.47% 5.23% 3.18% 7.18% 4.69%
Free Cash Flow per Share
3.17 1.67 3.12 2.15 1.26 3.43 5.81 3.60 7.15 4.94
Book value per Share
14.57 12.66 10.09 10.14 10.04 15.12 18.19 14.83 18.31 21.05
Free Cash Flow
8,762.00 4,563.00 8,307.00 5,515.00 3,188.00 8,674.00 14,707.00 9,143.00 18,096.00 12,360.00
EV/EBIT
31.01 23.68 23.22 29.95 39.12 16.40 16.24 106.26 13.48 13.37
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026